Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: J Prev Alzheimers Dis. 2023;10(2):193–206. doi: 10.14283/jpad.2023.8

Table 1.

Cumulative incidence of dementias by vascular diseases in men with prostate cancer with up to 26 years of follow-up

Characteristics Cumulative incidence (row %) of ADRD*
AD Vascular DLB FTD MCI Others Total
Cardiovascular disease
 No 9.95 4.50 1.19 0.23 2.15 27.25 29.11
 Yes 10.34 5.47 0.96 0.20 1.92 31.65 33.80
Stroke
 No 9.50 4.05 1.13 0.22 2.05 26.25 28.03
 Yes 13.58 8.54 1.46 0.31 2.72 38.03 40.70
Hypertension
 No 9.73 4.11 1.15 0.21 1.93 25.54 27.31
 Yes 10.13 4.88 1.18 0.24 2.25 28.92 30.88
Diabetes
 No 9.90 4.38 1.21 0.23 2.12 26.87 28.68
 Yes 10.24 5.24 1.06 0.23 2.19 30.11 32.23
Age (years)
 65-69 5.22 2.57 0.87 0.21 1.71 17.02 18.46
 70-74 9.32 4.30 1.30 0.25 2.36 25.98 27.83
 75-79 13.52 6.06 1.40 0.26 2.50 34.48 36.61
 80-84 15.77 7.10 1.40 0.21 2.33 40.24 42.69
 85 or older 14.19 6.40 0.87 0.14 1.61 41.98 44.39
Race/ethnicity
 NH-Whites 9.90 4.39 1.22 0.25 2.26 27.43 29.3
 NH-Blacks 10.70 6.11 0.88 0.14 1.50 28.86 30.71
 NH-Asians/Pacific Islanders 9.03 4.12 0.95 0.16 1.68 26.10 28.13
 Hispanics 9.64 4.35 1.11 0.14 1.68 27.64 29.54
 Others 9.98 5.04 1.07 0.15 1.87 29.49 31.58
unknown/missing 11.36 5.06 1.27 0.27 2.62 30.2 32.23
Marital status
 Married 6.25 2.50 1.01 0.23 2.27 19.15 20.80
 Unmarried 12.67 6.22 1.31 0.23 2.04 34.00 36.07
 Unknown 10.42 4.37 1.10 0.21 2.11 27.73 29.61
Tumor stage
 Local/Regional 10.18 4.64 1.24 0.24 2.26 27.72 29.60
 Distant 4.46 2.46 0.30 0.08 0.75 20.90 22.24
 Unknown/missing 12.60 6.03 0.96 0.15 1.61 33.56 35.99
Tumor grade
 Well-differentiated 11.59 6.15 0.94 0.18 1.12 29.16 31.12
 Moderately-differentiated 11.33 5.14 1.38 0.27 2.34 29.71 31.64
 Poorly-differentiated 8.19 3.61 1.00 0.19 2.17 24.60 26.41
 Unknown/Missing 9.70 5.09 0.91 0.18 1.41 29.88 31.85
Chemotherapy
 No 9.32 4.36 1.11 0.23 2.06 25.58 27.44
 Yes 11.12 4.97 1.27 0.23 2.25 31.19 33.13
Radiotherapy
 No 10.30 4.84 1.12 0.21 1.91 28.63 30.52
 Yes 9.61 4.30 1.23 0.24 2.39 26.50 28.39
Androgen deprivation therapy
 No 9.29 4.33 1.11 0.23 2.09 25.68 27.54
 Yes 11.41 5.12 1.28 0.23 2.23 31.74 33.68
Comorbidity Scores
 0 9.75 4.36 1.19 0.23 2.20 26.08 27.91
 1 10.78 5.10 1.16 0.23 2.01 31.41 33.41
 ≥2 10.21 5.65 0.94 0.16 1.77 34.12 36.31
SEER Areas
 Connecticut 11.53 7.91 1.29 0.42 2.21 32.00 34.07
 Detroit 16.77 8.60 1.56 0.22 1.96 38.62 40.83
 Hawaii 12.18 7.03 0.92 0.16 2.29 32.25 34.31
 Iowa 10.28 4.06 1.40 0.21 1.64 30.25 31.68
 New Mexico 10.16 4.76 1.14 0.12 1.86 31.82 33.44
 Seattle 5.76 2.86 0.45 0.11 1.00 16.29 17.82
 Utah 9.48 3.64 0.99 0.17 1.70 27.83 29.56
 Georgia 6.77 2.42 0.55 0.21 1.34 19.38 20.92
 Kentucky 9.86 3.11 1.35 0.22 1.45 28.71 29.95
 Louisiana 6.19 2.54 0.70 0.08 1.06 18.04 19.42
 New Jersey 11.21 5.06 1.43 0.29 3.03 28.56 30.94
 California 9.38 4.09 1.29 0.25 2.79 27.88 29.96
Total 9.98 4.59 1.17 0.23 2.13 27.65 29.54
*

ADRD (Alzheimer’s disease and related dementias), AD (Alzheimer’s disease), Vascular (vascular dementia), DLB (dementia with Lewy bodies), FTD (Frontotemporal degeneration and dementias), MCI (Mild cognitive impairment), others (other dementias), and total (any of above ADRD).